Novanta's second quarter revenue of $266M and EPS of $0.89 beat estimates, driven by strong 9.3% organic growth.

Novanta reported second quarter 2026 revenue of $265.8 million, up 10.3% year-over-year, with adjusted EPS increasing 17.1% to $0.89. Both figures surpassed analyst expectations, leading the company to raise its full-year guidance.

Key Highlights

• Organic revenue grew 9.3% year-over-year, exceeding the company's guided range of 6% to 8% and marking the strongest organic growth since the first quarter of 2023.
• Adjusted EBITDA increased 16.4% to $60.7 million, with the corresponding margin expanding to 22.8% from the prior year.
• Novanta raised its full-year 2026 guidance to revenue of $1.13 billion to $1.14 billion and adjusted EPS of $3.68 to $3.74, incorporating the impact of the recent Riverpoint Medical acquisition.